OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• OptimizeRx Corp. has received a consensus recommendation of "Moderate Buy" from analysts, with three recommending a hold and eight suggesting a buy.
• The average 12-month price target for OptimizeRx shares among analysts is $11.81, while the company's stock has shown a twelve-month high of $18.22.
• JPMorgan Chase & Co. significantly increased its holdings in OptimizeRx by 670.3% during the 4th quarter, indicating strong institutional interest in the company.

Shares of OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven analysts that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.8125.

Several brokerages have recently issued reports on OPRX. Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Roth Capital reiterated a "buy" rating on shares of OptimizeRx in a report on Friday, August 8th. Stifel Nicolaus upped their price target on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, August 8th. B. Riley reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Wall Street Zen raised shares of OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

Institutional Trading of OptimizeRx

Several institutional investors have recently modified their holdings of OPRX. Nisa Investment Advisors LLC grew its stake in shares of OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company's stock worth $29,000 after purchasing an additional 1,818 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of OptimizeRx in the first quarter worth $33,000. Quantbot Technologies LP bought a new stake in shares of OptimizeRx in the second quarter worth $44,000. Wells Fargo & Company MN grew its stake in shares of OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after purchasing an additional 2,797 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock worth $55,000 after purchasing an additional 2,215 shares during the last quarter. Institutional investors own 76.47% of the company's stock.

OptimizeRx Price Performance

OPRX traded down $0.31 during trading on Friday, hitting $15.49. 300,215 shares of the stock traded hands, compared to its average volume of 413,296. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $18.22. The company has a market cap of $287.65 million, a price-to-earnings ratio of -28.68, a PEG ratio of 5.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The business has a 50 day moving average price of $13.89 and a 200 day moving average price of $10.44.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.